Evaluation of the efficacy of daikenchuto (TJ -100) for the prevention of paralytic ileus after pancreaticoduodenectomy: A multicenter, double-blind, randomized, placebo-controlled trial
Ken-ichi Okada, Manabu Kawai, Seiko Hirono, Tsutomu Fujii, Yasuhiro Kodera, Masayuki Sho, Yoshiyuki Nakajima, Sohei Satoi, A-Hon Kwon, Yasuhiro Shimizu, Yoshiyasu Ambo, Naru Kondo, Yoshiaki Murakami, Jiro Ohuchida, Hidetoshi Eguchi, Hiroaki Nagano, Mari S Oba, Satoshi Morita, Junichi Sakamoto, Hiroki Yamaue, JAPAN-PD Investigators, Ken-ichi Okada, Manabu Kawai, Seiko Hirono, Tsutomu Fujii, Yasuhiro Kodera, Masayuki Sho, Yoshiyuki Nakajima, Sohei Satoi, A-Hon Kwon, Yasuhiro Shimizu, Yoshiyasu Ambo, Naru Kondo, Yoshiaki Murakami, Jiro Ohuchida, Hidetoshi Eguchi, Hiroaki Nagano, Mari S Oba, Satoshi Morita, Junichi Sakamoto, Hiroki Yamaue, JAPAN-PD Investigators
Abstract
Background: We assessed the efficacy of TJ-100 taken perioperatively to recovery among patients with periampullary tumor or tumor of the head of the pancreas who underwent pancreaticoduodenectomy (PD).
Patients and methods: In this multicenter, randomized, double-blinded, placebo-controlled, phase II trial (JAPAN-PD Study), patients were assigned randomly in a 1:1 ratio to receive TJ-100 or placebo. The coprimary endpoints were (1) incidence of postoperative paralytic ileus lasting >72 hours after surgery and (2) time to occurrence of postoperative paralytic ileus. This trial is registered at the UMIN Clinical Trials Registry (000007975) and at ClinicalTrials.gov (NCT01607307).
Results: From August 2012 through July 2013, we assessed 273 patients for eligibility, and 224 underwent randomization; 112 patients received TJ-100, and 112 patients received placebo. The population for analysis consisted of 104 patients who received TJ-100 and 103 who received placebo. Paralytic ileus occurred 35 (33.7%) in the TJ-100 group and 38 (36.9%) in the placebo group (P = .626). Time to first flatus was 2.25 (2.00-2.50) days in the TJ-100 group and 2.50 (1.50-2.50) days in the placebo group (P = .343). Among 23 patients who underwent a pylorus ring-preserving PD, time to first flatus was lower in the TJ-100 group than in the placebo group: 0.50 (0.50-1.00) days versus 1.50 (0.50-3.00) days (P = .034).
Conclusion: Our findings suggest that use of TJ-100 did not improve recovery from paralytic ileus after PD, and may preclude the routine use of TJ-100 in clinical practice after PD operation.
Copyright © 2016 Elsevier Inc. All rights reserved.
Source: PubMed